Insights Into Cytokinetics Inc (CYTK) Exposure By Institutions

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

Cytokinetics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Cytokinetics Inc is $7.31B. A total of 1.04 million shares were traded on the day, compared to an average of 3.47M shares.

In the most recent transaction, Malik Fady Ibraham sold 32,604 shares of CYTK for 67.56 per share on Mar 05 ’24. After the transaction, the EVP Research & Development now owns 138,973 company shares. In a previous transaction on Feb 14 ’24, HENDERSON JOHN T sold 5,000 shares at 76.48 per share. CYTK shares that Director owns now total 42,632.

Among the insiders who sold shares, Blum Robert I disposed of 12,500 shares on Feb 13 ’24 at a per-share price of $76.85. This resulted in the President & CEO holding 441,797 shares of CYTK after the transaction. In another insider transaction, Malik Fady Ibraham sold 32,605 shares at $79.30 per share on Feb 06 ’24. Company shares held by the EVP Research & Development now total 142,973.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, CYTK has a high of $110.25 and a low of $25.98.

As of this writing, CYTK has an earnings estimate of -$1.14 per share for the current quarter. EPS was calculated based on a consensus of 14 estimates, with a high estimate of -$0.89 per share and a lower estimate of -$1.36. The company reported an EPS of -$1.35 in the last quarter, which was -82.40% lower than expectations of -$0.74.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. CYTK’s latest balance sheet shows that the firm has $471.64M in Cash & Short Term Investments as of fiscal 2021. There were $269.93M in debt and $71.86M in liabilities at the time. Its Book Value Per Share was -$3.80, while its Total Shareholder’s Equity was $243.86M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CYTK is Buy with a score of 4.56.

Most Popular

Related Posts